Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Bluebird Bio (NASDAQ: BLUE) on August 3. The company’s shares opened today at $157.30.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 10.6% and a 39.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $217.30 average price target, a 38.1% upside from current levels. In a report issued on August 2, William Blair also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Based on Bluebird Bio’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $146 million. In comparison, last year the company had a GAAP net loss of $70.9 million.
Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.
